Early spread of tumor cells is usually undetected by current imaging technologies. In patients with cancer and no signs of overt metastases sensitive methods have been developed to detect circulating tumor cells (CTCs) in the peripheral blood and disseminated tumor cells (DTCs) in the bone marrow. These technologies can be classified into cytometric and/or immunological and molecular approaches. Interestingly, the bone marrow seems to be a common homing tissue for cells derived from various epithelial tumors, and level 1a data from European and US groups have confirmed the prognostic impact of DTCs in the bone marrow of patients with breast cancer. Sequential peripheral blood analyses, however, are more convenient than bone marrow analyses for patients with solid tumors, and many research groups are currently assessing the clinical use of CTCs for assessment of prognosis and monitoring of systemic therapy. Molecular characterization of DTCs and CTCs opens a new avenue for understanding cancer dormancy, and might contribute to the identification of metastatic stem cells with important implications for future therapies. This Review focuses on the clinical relevance of the latest research results on blood-borne cancer micrometastases in patients with cancer.
Cytometric/immunological and molecular approaches are the major methods to detect single DTCs/CTCs within bone marrow or blood cells
These technologies provide the potential to monitor systemic tumor-cell dissemination as one of the first crucial steps in the metastatic cascade
Various clinical studies demonstrated level 1a evidence for an association between the presence of DTCs in bone marrow and postoperative metastatic relapse, particularly in patients with breast cancer
Many research groups are assessing the clinical use of CTC detection in the peripheral blood for prognosis prediction and real-time monitoring of systemic therapies, with promising results
The assessment and monitoring of therapeutic targets on CTCs (and probably DTCs) might become an important future diagnostic tool to guide treatment decisions before the onset of overt metastases
The molecular characterization of DTCs/CTCs might contribute to a greater understanding of cancer dormancy and the role of metastatic stem cells, with important implications for future therapies
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Pantel, K., Brakenhoff, R. H. & Brandt, B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat. Rev. Cancer 8, 329–340 (2008).
Zach, O. & Lutz, D. Tumor cell detection in peripheral blood and bone marrow. Curr. Opin. Oncol. 18, 48–56 (2006).
Herbert, G. S., Sohn, V. Y. & Brown, T. A. The impact of nodal isolated tumor cells on survival of breast cancer patients. Am. J. Surg. 193, 571–573 (2007).
Imoto, S., Ochiai, A., Okumura, C., Wada, N. & Hasebe, T. Impact of isolated tumor cells in sentinel lymph nodes detected by immunohistochemical staining. Eur. J. Surg. Oncol. 32, 1175–1179 (2006).
Kahn, H. J. et al. Biological significance of occult micrometastases in histologically negative axillary lymph nodes in breast cancer patients using the recent American Joint Committee on Cancer breast cancer staging system. Breast J. 12, 294–301 (2006).
Izbicki, J. R. et al. Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N. Engl. J. Med. 337, 1188–1194 (1997).
Kubuschok, B., Passlick, B., Izbicki, J. R., Thetter, O. & Pantel, K. Disseminated tumor cells in lymph nodes as a determinant for survival in surgically resected non-small-cell lung cancer. J. Clin. Oncol. 17, 19–24 (1999).
Bogoevski, D. et al. Mode of spread in the early phase of lymphatic metastasis in pancreatic ductal adenocarcinoma: prognostic significance of nodal microinvolvement. Ann. Surg. 240, 993–1000 (2004).
Weaver, D. L. et al. Detection of occult sentinel lymph node micrometastases by immunohistochemistry in breast cancer. An NSABP protocol B-32 quality assurance study. Cancer 107, 661–667 (2006).
Wada, N. & Imoto, S. Clinical evidence of breast cancer micrometastasis in the era of sentinel node biopsy. Int. J. Clin. Oncol. 13, 24–32 (2008).
Pinzani, P. et al. Isolation by size of epithelial tumor cells in peripheral blood of patients with breast cancer: correlation with real-time reverse transcriptase-polymerase chain reaction results and feasibility of molecular analysis by laser microdissection. Hum. Pathol. 37, 711–718 (2006).
Wong, N. S. et al. Prognostic significance of circulating tumour cells enumerated after filtration enrichment in early and metastatic breast cancer patients. Breast Cancer Res. Treat. 99, 63–69 (2006).
Zheng, S. et al. Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells. J. Chromatogr. A 1162, 154–161 (2007).
Woelfle, U. et al. Bi-specific immunomagnetic enrichment of micrometastatic tumour cell clusters from bone marrow of cancer patients. J. Immunol. Methods 300, 136–145 (2005).
Fehm, T. et al. A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer 107, 885–892 (2006).
Borgen, E. et al. A European interlaboratory testing of three well-known procedures for immunocytochemical detection of epithelial cells in bone marrow. Results from analysis of normal bone marrow. Cytometry B. Clin. Cytom. 70, 400–409 (2006).
Hayes, D. F. et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin. Cancer Res. 12, 4218–4224 (2006).
Riethdorf, S. et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch System. Clin. Cancer Res. 13, 920–928 (2007).
Shaffer, D. R. et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin. Cancer Res. 13, 2023–2029 (2007).
Sastre, J. et al. Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. Ann. Oncol. 19, 935–938 (2008).
Alix-Panabieres, C. et al. Detection and characterization of putative metastatic precursor cells in cancer patients. Clin. Chem. 53, 537–539 (2007).
Nagrath, S. et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450, 1235–1239 (2007).
Pachmann, K. et al. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J. Clin. Oncol. 26, 1208–1215 (2008).
Krivacic, R. T. et al. A rare-cell detector for cancer. Proc. Natl Acad. Sci. USA 101, 10501–10504 (2004).
Hsieh, H. B. et al. High speed detection of circulating tumor cells. Biosens. Bioelectron. 21, 1893–1899 (2006).
Ntouroupi, T. G. et al. Detection of circulating tumour cells in peripheral blood with an automated scanning fluorescence microscope. Br. J. Cancer 99, 789–795 (2008).
Deng, G. et al. Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients. Breast Cancer Res. 10, R69 (2008).
Mani, S. A. et al. The epithelial–mesenchymal transition generates cells with properties of stem cells. Cell 133, 704–715 (2008).
Alix-Panabières, C. et al. Detection of circulating prostate-specific antigen-secreting cells in prostate cancer patients. Clin. Chem. 51, 1538–1541 (2005).
Aguirre-Ghiso, J. A. Models, mechanisms and clinical evidence for cancer dormancy. Nat. Rev. Cancer 7, 834–846 (2007).
Hermanek, P., Hutter, R. V., Sobin, L. H. & Wittekind, C. International Union Against Cancer. Classification of isolated tumor cells and micrometastasis. Cancer 86, 2668–2673 (1999).
Singletary, S. E., Greene, F. L. & Sobin, L. H. Classification of isolated tumor cells: clarification of the 6th edition of the American Joint Committee on Cancer Staging Manual. Cancer 98, 2740–2741 (2003).
Braun, S. et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N. Engl. J. Med. 353, 793–802 (2005).
Bidard, F. C. et al. Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse. Clin. Cancer Res. 14, 3306–3311 (2008).
Muller, V. et al. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin. Cancer Res. 11, 3678–3685 (2005).
Wiedswang, G. et al. Comparison of the clinical significance of occult tumor cells in blood and bone marrow in breast cancer. Int. J. Cancer 118, 2013–2019 (2006).
Benoy, I. H. et al. Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer. Br. J. Cancer 94, 672–680 (2006).
Bidard, F. C. et al. Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells. Ann. Oncol. 19, 496–500 (2008).
Meng, S. et al. Circulating tumor cells in patients with breast cancer dormancy. Clin. Cancer Res. 10, 8152–8162 (2004).
Mehes, G., Witt, A., Kubista, E. & Ambros, P. F. Circulating breast cancer cells are frequently apoptotic. Am. J. Pathol. 159, 17–20 (2001).
Stathopoulou, A. et al. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J. Clin. Oncol. 20, 3404–3412 (2002).
Pierga, J. Y. et al. Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clin. Cancer Res. 10, 1392–1400 (2004).
Wikman, H., Vessella, R. & Pantel, K. Cancer micrometastasis and tumor dormancy. APMIS 116, 754–770 (2008).
Cristofanilli, M. et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351, 781–791 (2004).
Budd, G. T. et al. Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. Clin. Cancer Res. 12, 6403–6409 (2006).
Harris, L. et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 25, 5287–5312 (2007).
[No authors listed.] Treatment decision making based on blood levels of tumor cells in women with metastatic breast cancer receiving chemotherapy. SWOG-S0500. National Cancer Institute [online], (2006).
Pierga, J. Y. et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin. Cancer Res. 14, 7004–7010 (2008).
Mueller, V. et al. Prospective monitoring of circulating tumor cells in breast cancer patients treated with primary systemic therapy—a translational project of the German breast Group study GeparQuattro [Abstract]. ASCO Meeting Abstracts 25, 21085 (2007).
Rack, B. K. et al. Prognostic relevance of circulating tumor cells (CTCs) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy: The German SUCCESS-Trial [Abstract]. ASCO Meeting Abstracts 26, 503 (2008).
Pantel, K. et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J. Natl Cancer Inst. 85, 1419–1424 (1993).
Gralow, J. et al. Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening—a report from the American Society of Clinical Oncology. J. Clin. Oncol. 26, 313–325 (2008).
Piccart-Gebhart, M. J. et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659–1672 (2005).
Braun, S. et al. ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I–III breast cancer patients. Cancer Res. 61, 1890–1895 (2001).
Wülfing, P. et al. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin. Cancer Res. 12, 1715–1720 (2006).
Solomayer, E. F. et al. Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients. Breast Cancer Res. Treat. 98, 179–184 (2006).
Fehm, T. et al. Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res. 9, R74 (2007).
Simon, R. et al. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J. Natl Cancer Inst. 93, 1141–1146 (2001).
Gong, Y., Booser, D. J. & Sneige, N. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 103, 1763–1769 (2005).
Palmieri, D. et al. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res 67, 4190–4198 (2007).
Lower, E. E., Glass, E., Blau, R. & Harman, S. HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res. Treat. 113, 301–306 (2008).
Santinelli, A., Pisa, E., Stramazzotti, D. & Fabris, G. HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy. Int. J. Cancer 122, 999–1004 (2008).
Tapia, C. et al. HER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Res. 9, R31 (2007).
Press, M. F. et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin. Cancer Res. 11, 6598–6607 (2005).
Stoecklein, N. H. et al. Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell 13, 441–453 (2008).
Meng, S. et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc. Natl Acad. Sci. USA 101, 9393–9398 (2004).
Meng, S. et al. uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc. Natl Acad. Sci. USA 103, 17361–17365 (2006).
Janni, W. et al. The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer 103, 884–891 (2005).
Hanrahan, E. O. et al. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J. Clin. Oncol. 25, 4952–4960 (2007).
Koebel, C. M. et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450, 903–907 (2007).
Mahnke, Y. D., Schwendemann, J., Beckhove, P. & Schirrmacher, V. Maintenance of long-term tumour-specific T-cell memory by residual dormant tumour cells. Immunology 115, 325–336 (2005).
Condeelis, J. & Pollard, J. W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124, 263–266 (2006).
Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960–1964 (2006).
Kaplan, R. N. et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438, 820–827 (2005).
Steeg, P. S. Tumor metastasis: mechanistic insights and clinical challenges. Nat. Med. 12, 895–904 (2006).
Gao, D. et al. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 319, 195–198 (2008).
Kallergi, G. et al. Vascular endothelial growth factor (VEGF) expression in CTCs of breast cancer patients [Abstract]. AACR Meeting Abstracts 276 (2008).
Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 860–867 (2002).
Chang, H. Y. et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol. 2, E7 (2004).
Clarke, M. F. & Fuller, M. Stem cells and cancer: two faces of eve. Cell 124, 1111–1115 (2006).
Trumpp, A. & Wiestler, O. D. Mechanisms of Disease: cancer stem cells-—targeting the evil twin. Nat. Clin. Pract. Oncol. 5, 337–347 (2008).
Liu, R. et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N. Engl. J. Med. 356, 217–226 (2007).
Ginestier, C. et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1, 555–567 (2007).
Becker, S., Becker-Pergola, G., Wallwiener, D., Solomayer, E. F. & Fehm, T. Detection of cytokeratin-positive cells in the bone marrow of breast cancer patients undergoing adjuvant therapy. Breast Cancer Res. Treat. 97, 91–96 (2006).
Becker, S., Solomayer, E., Becker-Pergola, G., Wallwiener, D. & Fehm, T. Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients. Breast Cancer Res. Treat. 106, 239–243 (2007).
Wiedswang, G. et al. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J. Clin. Oncol. 21, 3469–3478 (2003).
Braun, S., Hepp, F., Sommer, H. L. & Pantel, K. Tumor-antigen heterogeneity of disseminated breast cancer cells: implications for immunotherapy of minimal residual disease. Int. J. Cancer 84, 1–5 (1999).
Balic, M. et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin. Cancer Res. 12, 5615–5621 (2006).
Theodoropoulos, P. A. et al. Detection of circulating tumor cells with breast cancer stem cell-like phenotype in blood samples of patients with breast cancer [Abstract]. AACR Meeting Abstracts 2008 (2008).
Solakoglu, O. et al. Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors. Proc. Natl Acad. Sci. USA 99, 2246–2251 (2002).
Pantel, K. & Brakenhoff, R. H. Dissecting the metastatic cascade. Nat. Rev. Cancer 4, 448–456 (2004).
Wilson, A. & Trumpp, A. Bone-marrow haematopoietic-stem-cell niches. Nat. Rev. Immunol. 6, 93–106 (2006).
Thurm, H. et al. Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy. Clin. Cancer Res. 9, 2598–2604 (2003).
Hemsen, A. et al. Comparative evaluation of urokinase-type plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells. Int. J. Cancer 107, 903–909 (2003).
Reimers, N. et al. Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells. Clin. Cancer Res. 10, 3422–3428 (2004).
Pantel, K. et al. Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res. 51, 4712–4715 (1991).
Kang, Y. & Massague, J. Epithelial–mesenchymal transitions: twist in development and metastasis. Cell 118, 277–279 (2004).
Watson, M. A. et al. Isolation and molecular profiling of bone marrow micrometastases identifies TWIST1 as a marker of early tumor relapse in breast cancer patients. Clin. Cancer Res. 13, 5001–5009 (2007).
Klein, C. A. Random mutations, selected mutations: A PIN opens the door to new genetic landscapes. Proc. Natl Acad. Sci. USA 103, 18033–18034 (2006).
Fehm, T. et al. Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin. Cancer Res. 8, 2073–2084 (2002).
Maheswaran, S. et al. Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 359, 366–377 (2008).
Korah, R., Choi, L., Barrios, J. & Wieder, R. Expression of FGF-2 alters focal adhesion dynamics in migration-restricted MDA-MB-231 breast cancer cells. Breast Cancer Res. Treat. 88, 17–28 (2004).
Joensuu, K., Heikkilä, P. & Andersson, L. C. Tumor dormancy: Elevated expression of stanniocalcins in late relapsing breast cancer. Cancer Lett. 265, 76–83 (2008).
Heiss, M. M. et al. Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nat. Med. 1, 1035–1039 (1995).
Apostolaki, S. et al. Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance. Ann. Oncol. 18, 851–858 (2007).
Davis, J. W. et al. Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer. J. Urol. 179, 2187–2191 (2008).
Alix-Panabières, C. et al. Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients. J. Immunol. Methods 299, 177–188 (2005).
Rolle, A. et al. Increase in number of circulating disseminated epithelial cells after surgery for non-small cell lung cancer monitored by MAINTRAC(R) is a predictor for relapse: A preliminary report. World J. Surg. Oncol. 3, 18 (2005).
Gaforio, J. J. et al. Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen-receptor status and predicts for poor prognosis. Int. J. Cancer 107, 984–990 (2003).
Jotsuka, T. et al. Persistent evidence of circulating tumor cells detected by means of RT-PCR for CEA mRNA predicts early relapse: a prospective study in node-negative breast cancer. Surgery 135, 419–426 (2004).
Giatromanolaki, A. et al. Assessment of highly angiogenic and disseminated in the peripheral blood disease in breast cancer patients predicts for resistance to adjuvant chemotherapy and early relapse. Int. J. Cancer 108, 620–627 (2004).
Ferrucci, P. F. et al. Mammaglobin expression in leukapheresis products is a predictive marker of poor prognosis in women with high-risk breast cancer. Clin. Cancer Res. 10, 6039–6046 (2004).
Quintela-Fandino, M. et al. Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell support. J. Clin. Oncol. 24, 3611–3618 (2006).
Xenidis, N. et al. Clinical relevance of circulating CK-19 mRNA-positive cells detected during the adjuvant tamoxifen treatment in patients with early breast cancer. Ann. Oncol. 18, 1623–1631 (2007).
Ignatiadis, M. et al. Molecular detection and prognostic value of circulating cytokeratin-19 messenger RNA-positive and HER2 messenger RNA-positive cells in the peripheral blood of women with early-stage breast cancer. Clin. Breast Cancer 7, 883–889 (2007).
Ignatiadis, M. et al. Different prognostic value of cytokeratin-19 mRNA-positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. J. Clin. Oncol. 25, 5194–5202 (2007).
Nakagawa, T. et al. Detection of circulating tumor cells in early-stage breast cancer metastasis to axillary lymph nodes. Clin. Cancer Res. 13, 4105–4110 (2007).
Ignatiadis, M. et al. Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin. Cancer Res. 14, 2593–2600 (2008).
Cohen, S. J. et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 3213–3221 (2008).
Uen, Y. H. et al. Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection. Ann. Surg. 246, 1040–1046 (2007).
Sadahiro, S. et al. Detection of carcinoembryonic antigen messenger RNA-expressing cells in peripheral blood 7 days after curative surgery is a novel prognostic factor in colorectal cancer. Ann. Surg. Oncol. 14, 1092–1098 (2007).
Allen-Mersh, T. G. et al. Role of circulating tumour cells in predicting recurrence after excision of primary colorectal carcinoma. Br. J. Surg. 94, 96–105 (2007).
Iinuma, H. et al. Usefulness and clinical significance of quantitative real-time RT-PCR to detect isolated tumor cells in the peripheral blood and tumor drainage blood of patients with colorectal cancer. Int. J. Oncol. 28, 297–306 (2006).
Sadahiro, S. et al. Detection of carcinoembryonic antigen messenger RNA-expressing cells in portal and peripheral blood during surgery does not influence relapse in colorectal cancer. Ann. Surg. Oncol. 12, 988–994 (2005).
Kienle, P. et al. Decreased detection rate of disseminated tumor cells of rectal cancer patients after preoperative chemoradiation: a first step towards a molecular surrogate marker for neoadjuvant treatment in colorectal cancer. Ann. Surg. 238, 324–330 (2003).
Sadahiro, S. et al. Detection of tumor cells in the portal and peripheral blood of patients with colorectal carcinoma using competitive reverse transcriptase-polymerase chain reaction. Cancer 92, 1251–1258 (2001).
Sienel, W., Seen-Hibler, R., Mutschler, W., Pantel, K. & Passlick, B. Tumour cells in the tumour draining vein of patients with non-small cell lung cancer: detection rate and clinical significance. Eur. J. Cardiothorac. Surg. 23, 451–456 (2003).
Yamashita, J. et al. Preoperative evidence of circulating tumor cells by means of reverse transcriptase-polymerase chain reaction for carcinoembryonic antigen messenger RNA is an independent predictor of survival in non-small cell lung cancer: a prospective study. J. Thorac. Cardiovasc. Surg. 124, 299–305 (2002).
Sher, Y. P. et al. Prognosis of non-small cell lung cancer patients by detecting circulating cancer cells in the peripheral blood with multiple marker genes. Clin. Cancer Res. 11, 173–179 (2005).
Yamamoto, O. et al. Surfactant protein gene expressions for detection of lung carcinoma cells in peripheral blood. Respir. Med. 99, 1164–1174 (2005).
Sheu, C. C. et al. Development of a membrane array-based multimarker assay for detection of circulating cancer cells in patients with non-small cell lung cancer. Int. J. Cancer 119, 1419–1426 (2006).
Sheu, C. C. et al. Combined detection of CEA, CK-19 and c-met mRNAs in peripheral blood: a highly sensitive panel for potential molecular diagnosis of non-small cell lung cancer. Oncology 70, 203–211 (2006).
Chen, T. F. et al. CK19 mRNA expression measured by reverse-transcription polymerase chain reaction (RT-PCR) in the peripheral blood of patients with non-small cell lung cancer treated by chemo-radiation: an independent prognostic factor. Lung Cancer 56, 105–114 (2007).
Liu, L. et al. Detection of circulating cancer cells in lung cancer patients with a panel of marker genes. Biochem. Biophys. Res. Commun. 372, 756–760 (2008).
Olmos, D. et al. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann. Oncol. 20, 27–33 (2008).
Okegawa, T., Nutahara, K. & Higashihara, E. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer. J. Urol. 180, 1342–1347 (2008).
Danila, D. C. et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin. Cancer Res. 13, 7053–7058 (2007).
Moreno, J. G. et al. Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology 65, 713–718 (2005).
Ross, R. W. et al. Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy. Clin. Cancer Res. 11, 5195–5198 (2005).
Gewanter, R. M. et al. RT-PCR for PSA as a prognostic factor for patients with clinically localized prostate cancer treated with radiotherapy. Urology 61, 967–971 (2003).
Tombal, B., Van Cangh, P. J., Loric, S. & Gala, J. L. Prognostic value of circulating prostate cells in patients with a rising PSA after radical prostatectomy. Prostate 56, 163–170 (2003).
Mejean, A. et al. Detection of circulating prostate derived cells in patients with prostate adenocarcinoma is an independent risk factor for tumor recurrence. J. Urol. 163, 2022–2029 (2000).
Grasso, Y. Z., Gupta, M. K., Levin, H. S., Zippe, C. D. & Klein, E. A. Combined nested RT-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in prostate cancer patients: correlation with pathological stage. Cancer Res. 58, 1456–1459 (1998).
Ghossein, R. A. et al. Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma. Urology 50, 100–105 (1997).
Olsson, C. A. et al. Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy. J. Urol. 155, 1557–1562 (1996).
This work was supported by grants from the Deutsche Forschungsgemeinschaft (PA 341/15-2), Deutsche Krebshilfe (10-2181-Pa) Bonn, Germany; and the European Commission (DISMAL-project, contract no. LSHC-CT-2005-018911).
The authors declare no competing financial interests.
About this article
Cite this article
Pantel, K., Alix-Panabières, C. & Riethdorf, S. Cancer micrometastases. Nat Rev Clin Oncol 6, 339–351 (2009). https://doi.org/10.1038/nrclinonc.2009.44
Prospective Comparison of the Prognostic Relevance of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow of a Single Patient's Cohort With Esophageal Cancer
Annals of Surgery (2021)
Cysteine-Rich Angiogenic Inducer 61: Pro-Survival Function and Role as a Biomarker for Disseminating Breast Cancer Cells
Journal of Materials Chemistry C (2021)
Nature Reviews Cancer (2021)